Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT.

MLA

Hirabayashi, Shigeki, et al. “Personalized Prediction of Overall Survival in Patients with AML in Non‐complete Remission Undergoing Allo‐HCT.” Cancer Medicine, vol. 10, no. 13, July 2021, pp. 4250–68. EBSCOhost, https://doi.org/10.1002/cam4.3920.

APA

Hirabayashi, S., Uozumi, R., Kondo, T., Arai, Y., Kawata, T., Uchida, N., Marumo, A., Ikegame, K., Fukuda, T., Eto, T., Tanaka, M., Wake, A., Kanda, J., Kimura, T., Tabuchi, K., Ichinohe, T., Atsuta, Y., Yanada, M., & Yano, S. (2021). Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT. Cancer Medicine, 10(13), 4250–4268. https://doi.org/10.1002/cam4.3920

Chicago

Hirabayashi, Shigeki, Ryuji Uozumi, Tadakazu Kondo, Yasuyuki Arai, Takahito Kawata, Naoyuki Uchida, Atsushi Marumo, et al. 2021. “Personalized Prediction of Overall Survival in Patients with AML in Non‐complete Remission Undergoing Allo‐HCT.” Cancer Medicine 10 (13): 4250–68. doi:10.1002/cam4.3920.